Division of Nephrology, Department of Internal Medicine, Show Chwan Memorial Hospital, Changhua City, Taiwan.
Horm Metab Res. 2013 Jan;45(1):38-42. doi: 10.1055/s-0032-1321871. Epub 2012 Sep 6.
The present study was designed to investigate the role of TNF-α in renal damage observed in mice with hepatic steatosis. We induced hepatic steatosis in mice using high fat diet and treated mice with ectanercept at the dose sufficient to block TNF-α receptors or vehicle for 1 month. Plasma TNF-α, total cholesterol (TC), triglyceride (TG), LDL-cholesterol (LDL-C), and HDL-cholesterol (HDL-C) were determined at the end of this treatment. Renal damage was identified by histologic observation and the higher of serum blood urea nitrogen (BUN) and creatinine. Also, changes of PPAR-δ in kidney and renal mesangial cell (RMC) were analyzed using Western blot. Plasma TNF-α was markedly raised in mice showing hepatic steatosis. However, the levels of blood lipids (TC, TG, HDL-C, and LDL-C) and TNF-α were not modified by the treatment of etanercept although the hepatic steatosis has been improved. Etanercept shows renal protection from histological identification and recovery of serum BUN and creatinine levels. Moreover, restoration of PPAR-δ expression by etanercept was observed in mice kidney. Direct effect of TNF-α on PPAR-δ expression was also characterized in RMC cell. We suggest that renal damage in mice with hepatic steatosis is mainly induced by increase of TNF-α through the decrease of renal PPAR-δ. Etanercept could block TNF-α receptors to restore PPAR-δ and improve renal function in mice with hepatic steatosis.
本研究旨在探讨 TNF-α 在肝脂肪变性小鼠肾脏损伤中的作用。我们使用高脂肪饮食诱导小鼠肝脂肪变性,并使用足以阻断 TNF-α 受体的依那西普或载体治疗小鼠 1 个月。在治疗结束时测定血浆 TNF-α、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)。通过组织学观察和血清血尿素氮(BUN)和肌酐的升高来识别肾脏损伤。还使用 Western blot 分析了肾脏和肾小球系膜细胞(RMC)中 PPAR-δ 的变化。肝脂肪变性小鼠的血浆 TNF-α 明显升高。然而,依那西普治疗并未改变血脂(TC、TG、HDL-C 和 LDL-C)和 TNF-α 的水平,尽管肝脂肪变性已得到改善。依那西普可通过组织学鉴定和恢复血清 BUN 和肌酐水平来保护肾脏免受损伤。此外,在小鼠肾脏中观察到依那西普恢复了 PPAR-δ 的表达。TNF-α 对 PPAR-δ 表达的直接作用也在 RMC 细胞中得到了描述。我们认为,肝脂肪变性小鼠的肾脏损伤主要是由 TNF-α 增加通过降低肾脏 PPAR-δ 引起的。依那西普可以阻断 TNF-α 受体,恢复 PPAR-δ 并改善肝脂肪变性小鼠的肾功能。